Furthermore, the underlying mechanism of the catalytic therapy for psoriasis is the up-regulation of estrogen receptor 1 (ESR1) in the FeN4O2-SACs treatment, which is largely reduced in the clinical samples of psoriasis and relapse patients. This evidence concerns the gene ESR1 and psoriasis.